Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stem Cell Quantification After Filgrastim Mobilization
NCT03381599Phase 1Completed
- Sponsor
- Andrews Research & Education Foundation
- Start
- Mar 2018
- Primary completion
- Sep 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of filgrastim in orthopedic disorders, sponsored by Andrews Research & Education Foundation. Primary endpoint: Change in Stem Cell Count at Day 32. Started Mar 2018; status: completed.
02
Drugs
filgrastim
03
Conditions
orthopedic disorders
Beyond the preview
Go deeper on NCT03381599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381599.